Maxim initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $8 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics completes last patient visit in ATH434-201 trial
- Alterity Therapeutics appoints Abby Macnish Niven as secretary
- Alterity Therapeutics announces presentation on bioMUSE study
- Alterity Therapeutics announces new publication on ATH434
- Alterity Therapeutics reports cash balance of A$9.28M as of September 30